Synthetic peptide corresponding to aa650-700 near the center of SARS-CoV-2 UK variant (B.1.1.7) Spike protein.
Alternative Synonym:
covid-19, sars-cov-2
In September of 2020 a new lineage of SARS-CoV-2, known as B.1.1.7, was discovered in the United Kingdom. This lineage was found to have developed 14 lineage-specific amino acid replacements and 3 deletions prior to its discovery. The transmission of UK variant (B.1.1.7 lineage) was increased at least 50%. Increased severity and higher death rate were also found in UK variant. UK variant will not affect the effectiveness of COVID19 vaccine. One of the mutations associated with this lineage is a N501Y in the spike protein of the virus. It is believed that this mutation is able to increase the spike proteins affinity for the host ACE2 receptor and it has been associated with increased infectivity and virulence. B.1.1.7 viruses have also been shown to have a P681H in the cleavage site of spike protein. This location is one of the residues that make up the furin cleavage site between S1 and S2 in spike protein. Applications: Suitable for use in ELISA and Western Blot. Other applications not tested. Recommended Dilution: Western Blot: 1ug/ml Optimal dilutions to be determined by the researcher. Storage and Stability: May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
UniProt:
QHD43416
Reinheit:
Purified by immunoaffinity chromatography.
Formulierung:
Supplied as a liquid in PBS, 0.02% sodium azide.
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
